CDEK
← All drugs Report issue

calcipotriene

Trade name: dovonex

Small moleculeapproved

Approved

Dec 29, 1993

7Z-Calcipotriol is an isomeric impurity in vitamin D analog calcipotriol. Synthesis of 7Z-Calcipotriol was disclosed by Japanese company Kuraray Co in a patent application JP 06316558. — NCATS

Clinical trial activity

137 trials · 152 clinical orgs · 18 marketing orgs

Phase 1
42
Phase 2
58
Phase 3
32
Phase 4
25

Earliest trial started Nov 1, 2004 (NCT00216827)

Timeline

1990s

  1. Dec 29, 1993

    Leo Pharma — Earliest FDA Approval

  2. Dec 29, 1993

    Leo Pharma — NDA Organization

  3. Mar 3, 1997

    Leo Pharma — NDA Secondary Org

2000s

  1. Jan 1, 2004

    Leo Pharma — Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2005

    Leo Pharma — Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

  4. May 6, 2008

    Fougera — Marketing Organization

  5. Nov 19, 2009

    Hi Tech Pharmaceuticals — Marketing Organization

  6. Nov 19, 2009

    Akorn, Inc. — Marketing Organization

  7. Nov 19, 2009

    Hikma — Marketing Organization

  8. Nov 20, 2009

    Tolmar Inc. — Marketing Organization

  9. Nov 20, 2009

    Chartwell Pharmaceuticals — Marketing Organization

2010s

  1. Mar 24, 2010

    Glenmark Pharmaceuticals — Marketing Organization

  2. Oct 6, 2010

    Mayne Pharma — NDA Secondary Org

  3. Mar 24, 2011

    Cosette — Marketing Organization

  4. Mar 24, 2011

    ACP Nimble — Marketing Organization

  5. Mar 24, 2011

    G & W Laboratories Inc. — Marketing Organization

  6. Dec 12, 2014

    Perrigo — Marketing Organization

  7. Dec 12, 2014

    Padagis Us — Marketing Organization

  8. Dec 26, 2017

    Novel Anti-Infective Technologies, LLC — Marketing Organization

2020s

  1. Jul 20, 2020

    MC2 Therapeutics — NDA Secondary Org

  2. Sep 2, 2020

    Taro Pharmaceuticals — Marketing Organization

  3. Sep 2, 2020

    Sun Pharmaceuticals — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Combination products

Approval history

  • approvedDec 29, 1993

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]2CC[C@@H]3[C@]2(C)CCC\C3=C/C=C4/C[C@@H](O)C[C@H](O)C4=C
Mol. weight
412.6047 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 1,24(oh)2-22-ene-24-cyclopropyl d3
  • (5e)-calcipotriene
  • 9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1alpha,3beta,5z,7e,22e)-
  • betamethasone 17-valerate - clioquinol
  • betamethasone 17-valerate, clioquinol drug combination
  • betamethasone 17-valerate - neomycin
  • betamethasone 17-valerate, neomycin drug combination
  • betamethasone dipropionate and salicylic acid drug combination
  • betamethasone dipropionate, calcipotriol drug combination
  • betamethasone dipropionate - salicylic acid
  • betamethasone dipropionate, salicylic acid drug combination
  • betnovate-c
  • betnovate-c
  • betnovate-c
  • betnovate-n
  • betnovate-n
  • bristol-myers squibb brand of calcipotriene
  • calcipotriene
  • calcipotriene
  • calcipotriene
  • calcipotriene
  • calcipotriene
  • calcipotriene
  • calcipotriene
  • calcipotriene
  • calcipotriene
  • calcipotriene
  • calcipotriene hydrate
  • calcipotriene hydrate
  • calcipotriene hydrate
  • calcipotriol
  • calcipotriol
  • calcipotriol
  • calcipotriol
  • calcipotriol
  • calcipotriol
  • calcipotriol
  • calcipotriol hydrate
  • calcipotriol hydrate
  • calcipotriol hydrate
  • calciptriol
  • csl brand of calcipotriene
  • daivobet
  • daivobet
  • daivobet
  • daivonex
  • daivonex
  • daivonex
  • daivonex
  • diprosalic
  • diprosalic
  • diprosalic
  • dovobet
  • dovobet
  • dovobet
  • dovobet
  • dovonex
  • dovonex
  • dovonex
  • dovonex
  • dovonex
  • dovonex
  • enstilar
  • enstilar
  • enstilar
  • farmacusi brand of calcipotriene
  • heximar win care
  • leo brand of calcipotriene
  • mc 903
  • mc-903
  • mc-903
  • mc-903
  • pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (11beta,16beta)-, mixt. with 2-hydroxybenzoic acid
  • pri-2205
  • psorcutan
  • schering brand of calcipotriene
  • senosiain brand of calcipotriene
  • sorilux
  • sorilux
  • sorilux
  • u0267
  • xamiol
  • xamiol
  • xamiol gel

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06880042Early Phase 1 (Phase 1)Mar 11, 2025Post-Graduate Medical Institute, Lahore
NCT06737406N/AFeb 1, 2025Mazandaran University of Medical Sciences
NCT06685588N/AJan 31, 2025National University of Ireland
NCT06499415Phase 4Sep 4, 2024Maastricht University
NCT05954104N/AJul 1, 2023—
NCT05919082Phase 3Jun 21, 2023Leo Pharma
NCT05416320Early Phase 1 (Phase 1)Jan 31, 2023Wake Forest University
NCT06329258Phase 4Dec 6, 2022Windsor Dermatology
NCT05381597Phase 2/Phase 3 (Phase 3)Oct 15, 2022Boston University
NCT05185258Phase 4Feb 16, 2022Aarhus University
NCT06327620N/AJan 15, 2022Mansoura University
NCT04839731Early Phase 1 (Phase 1)Apr 14, 2021Virginia Polytechnic Institute and State University
NCT04571151Phase 4Jan 31, 2021University of Tehran
NCT04227288Phase 4Dec 1, 2020University of Alabama, Birmingham
NCT04580537Phase 2Oct 2, 2020Leo Pharma, University of Copenhagen
NCT04555707Phase 4Jun 24, 2020Derm Research, PLLC, University of Tehran
NCT04372277Phase 4Apr 28, 2020Eli Lilly, Windsor Dermatology
NCT04275024N/AApr 14, 2020Guangdong Provincial Hospital of Traditional Chinese Medicine
NCT04221906Phase 1Jan 31, 2020Boston Pharmaceuticals
NCT04071106Phase 2/Phase 3 (Phase 3)Sep 1, 2019Zagazig University
Showing 20 of 137 trials
Page 1 / 7

Organizations

Research & Development (152)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Leo PharmaFor profit464152004
MC2 TherapeuticsFor profit7732017
GlaxoSmithKlineFor profit6032008
Derm Research, PLLCFor profit5512008
Windsor DermatologyAcademic/Hospital5422010
Bioskin GmbHFor profit4022007
Dong-A UniversityAcademic/Hospital3312012
Icahn School of Medicine at Mount SinaiAcademic/Hospital3132010
Mayne PharmaFor profit3212012
Stiefel LaboratoriesFor profit3312008
AbbottFor profit2122007
BayerFor profit2212013
GaldermaFor profit2122006
Glenmark PharmaceuticalsFor profit2212017
Guangdong Provincial Hospital of Traditional Chinese MedicineAcademic/Hospital2222018
Harvard UniversityAcademic/Hospital2122007
Haus BioceuticalsFor profit2212012
Henry Ford Health SystemAcademic/Hospital2012010
Northwestern UniversityAcademic/Hospital2122009
NovartisFor profit2222009
152 organizations
Page 1 / 8

Marketing (25)

OrganizationOrg typeRelationshipDate
ACP NimbleFor profitMKTGMar 24, 2011
Akorn, Inc.For profitMKTGNov 19, 2009
Chartwell PharmaceuticalsFor profitMKTGNov 20, 2009
CosetteFor profitMKTGMar 24, 2011
FougeraFor profitMKTGMay 6, 2008
G & W Laboratories Inc.For profitMKTGMar 24, 2011
Glenmark PharmaceuticalsFor profitSYNJun 9, 2015
Glenmark PharmaceuticalsFor profitMKTGMar 24, 2010
Glenmark PharmaceuticalsFor profitSYNMar 21, 2023
Glenmark PharmaceuticalsFor profitSYNJun 9, 2015
Hi Tech PharmaceuticalsFor profitMKTGNov 19, 2009
HikmaFor profitMKTGNov 19, 2009
Leo PharmaFor profitNDA2Mar 3, 1997
Leo PharmaFor profitNDADec 29, 1993
Leo PharmaFor profitSYNDec 29, 1993
MC2 TherapeuticsFor profitNDA2Jul 20, 2020
Mayne PharmaFor profitNDA2Oct 6, 2010
Novel Anti-Infective Technologies, LLCFor profitMKTGDec 26, 2017
Padagis UsFor profitMKTGDec 12, 2014
PerrigoFor profitMKTGDec 12, 2014
PerrigoFor profitSYNDec 12, 2014
Sun PharmaceuticalsFor profitMKTGSep 2, 2020
Taro PharmaceuticalsFor profitMKTGSep 2, 2020
Taro PharmaceuticalsFor profitSYNSep 2, 2020
Tolmar Inc.For profitMKTGNov 20, 2009